首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1593530

全球人类微生物组市场规模、份额和成长分析：按产品、按疾病、按类型、按最终用户、按地区 - 产业预测 (2024-2031)

Human Microbiome Market Size, Share, Growth Analysis, By Product (Drugs, Probiotics), By Disease (Infectious Dieases, Gastrointestinal Diseases), By Type, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月15日 | 出版商:

SkyQuest | 英文 201 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球人类微生物组市场规模估值为8亿美元，从2023年的10.1亿美元增长到2031年的97亿美元，在预测期内（2024-2031年）预计复合年增长率为31.80%。。

人类微生物组已成为一个极其重要的研究领域，特别是因为它对呼吸和免疫健康有重要影响。研究表明，肠道微生物组的组成，特别是放线菌、厚壁菌门和拟桿菌门的组成与呼吸问题之间存在相关性，而微生物组的健康在整体免疫中发挥重要作用。例如，微生物组疗法的进展开始增强对 SARS-CoV-2 等新兴病原体的免疫反应。此外，这场大流行提高了人们对微生物诊断和化学的认识，为微生物群研究和应用创造了一个强劲的市场。据国际糖尿病协会称，到2045年，20岁至79岁之间的6900万人将受到糖尿病的影响，即使在大流行后的情况下，这种趋势也可能会持续下去。此外，微生物群在营养食品和皮肤病治疗等多种健康应用中的使用不断增加，推动了人类微生物组市场的发展。技术创新，特别是次世代定序和先进的微生物表征方法，正在进一步推动该领域的成长。总体而言，健康意识、人口变化和技术进步的交叉凸显了人类微生物组市场显着扩张的潜力。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Seres Therapeutics, Inc.（US）
Ferring Pharmaceuticals（Switzerland）
Biomebank（Australia）
Nestle SA（Switzerland）
Sanofi（France）
Seed Health, Inc.（US）
Enterome（France）
Pendulum（US）
Quantbiome, Inc.（Dba Ombre）（US）
Vedanta Biosciences, Inc.（US）
Maat Pharma SA（France）
International Flavors & Fragrances, Inc.（US）
Optibiotx Health Plc（UK）
Synlogic, Inc.（US）
Guangzhou Zhiyi Biotechnology Co., Ltd.（China）
Aobiome（US）
Siolta Therapeutics（US）
Alveolus Bio, Inc.（US）
MRM Health NV（Belgium）
Biome Inc（US）
Sanzyme Biologics（India）
Biomx（Israel）
Nubiyota（US）
Quorum Innovations（US）

简介目录

Product Code: SQMIG35H2299

Global Human Microbiome Market size was valued at USD 0.8 Billion in 2022 and is poised to grow from USD 1.01 Billion in 2023 to USD 9.7 Billion by 2031, growing at a CAGR of 31.80% during the forecast period (2024-2031).

The human microbiome has emerged as a pivotal area of research, particularly due to its significant connections to respiratory and immune health. Studies have shown a correlation between gut microbiota composition-specifically populations of actinobacteria, firmicutes, and bacteroidetes-and respiratory issues, highlighting the critical role of microbiome health in overall immunity. For instance, advancements in microbiome therapies have been initiated to bolster immune response against emerging pathogens like SARS-CoV-2. Additionally, the pandemic has heightened awareness surrounding microbial diagnostics and chemistry, creating a robust market for microbiota research and applications. This trend is poised to continue in the post-pandemic landscape, fueled by an increasing prevalence of lifestyle-related diseases and an aging population, with projections estimating 69 million individuals aged 20-79 will have diabetes by 2045, according to the International Diabetes Association. Moreover, the human microbiome market is being propelled by the growing utilization of microbiota in diverse health applications, including dietary supplements and dermatological treatments. Technological innovations, particularly next-generation sequencing and advanced microbial characterization methods, are further facilitating growth within this sector. Overall, the intersection of health awareness, demographic shifts, and technological advancements underscores the potential for significant expansion in the human microbiome market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Microbiome Market Segmental Analysis

Global Human Microbiome Market is segmented by Product, Disease, Type, End User, and region. Based on Product, the market is segmented into Drugs, Probiotics, Prebiotics, and Synbiotics. Based on Disease, the market is segmented into Infectious Dieases, Gastrointestinal Diseases, Endocrine and Metabolic Disorders, and Other Diseases. Based on Type, the market is segmented into Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT), Live Biotherapeutic Product, and Others. Based on End User, the market is segmented into Hospitals and Clinics, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Human Microbiome Market

The rising incidence of chronic diseases, including gastrointestinal disorders, obesity, and diabetes, significantly propels the Global Human Microbiome market. As scientific research increasingly elucidates the relationship between gut microbiota and these health issues, there is a burgeoning demand for microbiome-based treatments and interventions. This trend is fueling interest among both healthcare professionals and patients, resulting in heightened investments in research and development, as well as the commercialization of microbiome-related products. Consequently, this market is experiencing robust growth, as stakeholders recognize the potential of microbiome-targeted therapies to address pressing health challenges and improve patient outcomes.

Restraints in the Global Human Microbiome Market

A significant restraint in the Global Human Microbiome market is the exorbitant costs associated with research and development. The intricate nature of studying microbial communities and effectively translating these insights into viable therapies necessitates substantial financial and technical resources. Furthermore, the lengthy process of clinical trials, coupled with stringent regulatory approvals, adds layers of expense and complexity, which can hinder innovation and timely market entry of new products. As companies grapple with these financial constraints, the pace of advancements within the human microbiome sector may be slowed, limiting the potential growth and evolution of therapies aimed at leveraging this complex ecosystem.

Market Trends of the Global Human Microbiome Market

The Global Human Microbiome Market is witnessing a significant trend towards personalized medicine, driven by advancements in understanding the intricate relationship between microbial composition and individual health. As researchers and pharmaceutical companies increasingly focus on tailoring therapeutic interventions to specific microbial profiles, this approach results in more precise treatments and diagnostics for microbiota-related conditions. Not only does this trend enhance the efficacy of therapeutic agents, but it also fosters the development of innovative strategies to address diverse health issues. Consequently, the market is poised for growth as personalized microbiome-based solutions become integral to modern healthcare practices.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Technology Analysis
Patent Analysis
Regulatory Landscape

Human Microbiome Market by Product

Market Overview
Drugs
Probiotics
Prebiotics
Synbiotics

Human Microbiome Market by Disease

Market Overview
Infectious Diseases
Gastrointestinal Diseases
Endocrine & Metabolic Disorders
Other Diseases

Human Microbiome Market by Type

Market Overview
Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT)
Live Biotherapeutic Product
Others

Human Microbiome Market by End User

Market Overview
Hospitals and Clinics
Long-Term Care Facilities
Other End Users

Human Microbiome Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Seres Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomebank (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle S.A. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seed Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Enterome (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pendulum (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quantbiome, Inc. (Dba Ombre) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vedanta Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Maat Pharma SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
International Flavors & Fragrances, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Optibiotx Health Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Synlogic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guangzhou Zhiyi Biotechnology Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aobiome (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siolta Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alveolus Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MRM Health NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biome Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanzyme Biologics (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomx (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nubiyota (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quorum Innovations (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments